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The quinolone class is one of the
more important classes of antimicro-
bial agents discovered in recent years
and one of the most widely used class-
es of antimicrobial drugs in clinical
medicine. Their broad spectrum of
activity and pharmacokinetic proper-
ties make the quinolone agents ideal
for treating a variety of infections.
Their clinical importance is further
demonstrated by their activity against
a wide range of diseases of public
health importance such as anthrax,
tuberculosis, bacterial pneumonia,
and sexually transmitted diseases.
Recent research has provided new
data on the agent’s structure-function
relationships, modes of action, resist-
ance, pharmacokinetics, and drug
interactions. The third edition of
Quinolone Antimicrobial Agents nice-
ly addresses these advances. The book
is organized into four sections, each
containing chapters written by leading
experts. 
Mechanisms and Spectrum of
Activity and Resistance, the first
major section, explores the basic biol-
ogy of the quinolone class. The inter-
relationships between structure,
antimicrobial activity, and side effects
associated with various side chain
positions of the quinolones are dis-
cussed here. Pertinent information on
the bacterial topoisomerases and
DNA gyrases, quinolone binding,
DNA/RNA synthesis inhibition, cell
death in the absence of protein synthe-
sis, specific mutations within the
quinolone resistance–determining
region, and mutations that lead to
altered access to target enzymes
(efflux systems) is also highlighted. 
In the next section, Pharmacology,
the intricate field of quinolone phar-
macokinetics (PK) and pharmacody-
namics (PD) is evaluated. Information
regarding absorption, distribution,
metabolism, and excretion in a range
of patient types is provided, followed
by data gathered from pharmacokinet-
ic/pharmacodynamic studies in a vari-
ety of models. This section also pro-
vides a review of the role of pharma-
cologic evaluation in optimizing ther-
apy. 
The last two sections of the book,
Clinical Applications and Adverse
and Other Effects, will be of particu-
lar interest to clinicians. The chapters
in this section include a comprehen-
sive reference on general considera-
tions, antimicrobial aspects, treatment
models, clinical and comparative
studies, and suggested treatment regi-
mens for a host of infections. The
chapter on adverse effects has been
greatly expanded from the second edi-
tion because a substantial body of new
information has since been gathered.
Topics covered here include allergic
reactions, effects on connective tissue
structures and pregnancy, phototoxic-
ity, and central nervous system and
immune system toxicity. 
The organization and content of
this text make it a superlative refer-
ence. The discussions on treatments
and adverse effects contain some of
the most current data available. The
field of antimicrobial resistance, how-
ever, is one of the most rapidly evolv-
ing areas with constant discoveries of
new cases and data. Users should
understand that while this text serves
as a valuable reference, other sources
should be consulted to ensure that the
most comprehensive data are
obtained. The references provided
throughout, however, give the reader
starting points to other literature. 
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Although scrapie, a prion disease
of sheep, has been recognized since
the 18th century, it was the dramatic
emergence of bovine spongiform
encephalopathy (BSE) in British cat-
tle in the late 1980s that brought the
dangers of prion diseases into promi-
nence. The subsequent spread of this
disease into humans as new variant
Creutzfeldt-Jakob disease (CJD)
remains one of the unsolved emerging
infectious disease mysteries of the
20th century. This issue (OIE
Scientific and Technical Review 22
[2003]) of the Scientific and
Technical Review of the Office
International des Epizooties comes 11
years after a previous issue about
BSE. Much has happened since then;
this multi-author volume provides an
excellent account of what is known
about prion diseases in animals,
including BSE, which has now spread
from the United Kingdom to 14 other
countries, and remains an important
risk to human health. As a conse-
quence of BSE emergence, research